The $12.8 billion merger between health insurer UnitedHealth Group and drug benefits manager Catamaran Corp. is the latest of a spate of deals in the pharmaceutical industry.
“Certainly it’s been a trend that’s been happening between manufacturers and supply chain partners,” says Charles Rhyee, an analyst with Cowen and Co. “There’s a lot going on in terms of jockeying for purchasing power.”
Both drug buyers and sellers want to scale up to get more leverage as drug prices rise, says Rhyee. UnitedHealth and Catamaran, a pharmacy benefits manager, will control up to a fifth of the industry’s business.
Mergers are also being driven by short supplies of certain generic drugs.
“There are companies out there acquiring manufacturing capacity for sterile injectibles, ophthalmology drugs, and topical drugs,” says Donald Ellis of Avondale Partners.
Those particular types of drugs are hard to manufacturer and have few suppliers, says Ellis. And shortages could grow now that some foreign firms have left the U.S. market.
At the same time, George Hill of Deutsche Bank says the Affordable Care Act has meant more patients and more prescriptions, “which makes more companies comfortable that future revenue and earnings trends are sustainable.”
Which means that mergers are likely to continue, analysts say.
We’re here to help you navigate this changed world and economy.
Our mission at Marketplace is to raise the economic intelligence of the country. It’s a tough task, but it’s never been more important.
In the past year, we’ve seen record unemployment, stimulus bills, and reddit users influencing the stock market. Marketplace helps you understand it all, will fact-based, approachable, and unbiased reporting.
Generous support from listeners and readers is what powers our nonprofit news—and your donation today will help provide this essential service. For just $5/month, you can sustain independent journalism that keeps you and thousands of others informed.